Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Filter By
2021
February
Media Release
/
Feb 16, 2021
Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)
Read More
January
Media Release
/
Jan 26, 2021
Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin
Read More
Media Release
/
Jan 26, 2021
Novartis 2020 Financial Results
Read More
2020
December
Media Release
/
Dec 17, 2020
Sandoz Canada receives authorization from Health Canada to launch new biosimilar Hyrimoz® (adalimumab)
Read More
August
Media Release
/
Aug 19, 2020
Sandoz Canada launches two new biosimilars Ziextenzo® and Riximyo®
Read More
July
Media Release
/
Jul 16, 2020
Novartis in Canada certified as a Great Place to Work® for a second consecutive year
Read More
June
Media Release
/
Jun 25, 2020
Sandoz Canada Launches The Biosimilars Generation
Read More
Media Release
/
Jun 24, 2020
Novartis In Canada once again named to the list of Best Workplaces TM in Quebec
Read More
Media Release
/
Jun 11, 2020
Sandoz Canada Launches Injectable PrAmoxicillin Sodium and Potassium Clavulanate for Hospital Use
Read More
Media Release
/
Jun 09, 2020
Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo® and Riximyo®
Read More
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
You are here
Home
›
